Psychiatric disorders during pregnancy

International Review of Psychiatry

Volumn 15, Issue 3, 2003, Pages 217-230

  Cott, Anisa D ^a,c   Wisner, K L ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UTERUS SPASMOLYTIC AGENT; VENLAFAXINE;

CLINICAL TRIAL; COMMUNICATION DISORDER; CONGENITAL MALFORMATION; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEEDING DISORDER; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IRRITABILITY; JAUNDICE; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE HYPOTONIA; NERVOUSNESS; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA; TERATOGENESIS;

EID: 0042623653     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/0954026031000136848     Document Type: Review

References (158)

1. ADDIS, A. & KOREN, G. (2000). Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychological Medicine, 30, 89-94.
2. ALLISTER, L., LESTER, B.M., CARR, S. & LIU, J. (2001). The effects of maternal depression on fetal heart rate response to vibroacoustic stimulation. Developmental Neuropsychology, 20(3), 639-651.
3. ALTSHULER, L., COHEN, L., SZUBA, M.P., BURT, V.K., GITLIN, M. & MINTZ, J. (1996). Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry, 153, 592-606.
4. ALTSHULER, L.L. & HENDRICK, V. (1996). Pregnancy and psychotropic medication: changes in blood levels. Journal of Clinical Psychopharmacology, 16, 78-80.
5. ALTSHULER, L.L., HENDRICK, V. & COHEN, L.S. (1998). Course of mood and anxiety disorders during pregnancy and the postpartum period. Journal of Clinical Psychiatry, 59(Suppl. 2), 29-33.
6. AMERICAN MEDICAL ASSOCIATION (1983). Drug interactions and adverse drug interactions. In: AMA Drug Evaluations (pp. 31-44). Chicago: American Medical Association.
7. APPLEBY, L. (1991). Suicide during pregnancy and in the first postnatal year. British Medical Journal, 302, 137-140.
8. AUERBACH, J.G., HANS, S.L., MARCUS, J., & MAEIR, S. (1992). Maternal psychotropic medication and neonatal behavior. Neurotoxicology & Teratology, 14, 399-406.
9. BALDESSARINI, R.J., TONDO, L. & VIGUERA, A.C. (1999). Effects of discontinuing lithium maintenance treatment. Bipolar Disorders, 1, 17-24.
10. BARLOW, S.M., KNIGHT, A.F. & SULLIVAN, F.M. (1979). Prevention by diazepam of adverse effects of maternal restraint stress on postnatal development and learning in the rat. Teratology, 19, 105-110.
11. BENNEDSEN, B.E. (1998). Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Research, 33, 1-26.
12. BENNEDSEN, B.E., MORTENSEN, P.B., OLESEN, A.V., HENRIKSEN, T.B. & FRYDENBERG, M. (2001). Obstetric complications in women with schizophrenia. Schizophrenia Research, 47, 167-175.
13. BIRNDORF, C.A., MADDEN, A., PORTERA, L. & LEON, A.C. (2001). Psychiatric symptoms, functional impairment, and receptivity toward mental health treatment among obstetrical patients. International Journal of Psychiatry & Medicine, 31, 355-365.
14. BLEHAR, M, DEPAULO, J., GERSHON, E., REICH, T., SIMPSON, S.C. & NURNBERGER, J.I., JR. (1988). Women with bipolar disorder: findings from the NIMH genetics initiative sample. Psychopharmacological Bulletin, 34, 239-243.
15. BOGARDUS, S., HOLMBOE, E. & JEKEL, J.F. (1999). Perils, pitfalls, and possibilities in talking about medical risk. Journal of the American Medical Association, 281, 1037-1041.
16. BROCKINGTON, I.F., OATES, M. & ROSE, G. (1990). Prepartum psychosis. Journal of Affective Disorders, 19, 31-35.
17. BROUGHER, J.C. (1960). Use of an anti-emetic agent in nausea and vomiting associated with pregnancy. Western Medicine, 1, 9.
18. BURKE, K.C., BURKE, J.D., RAE, D.S. & REGIER, D.A. (1991). Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Archive in General Psychiatry, 48, 789-795.
19. CHAMBERS, C.D., JOHNSON, K.A., DICK, L.N., FELIX, R.J. & JONES, K.L. (1996). Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine, 335, 1010-1015.
20. CHAMBLESS, D.L. & GILLIS, M.M. (1993). Cognitive therapy of anxiety disorders. Journal of Consulting and Clinical Psychology, 61, 248-260.
21. CHELMOW, D. & HALFIN, V.P. (1997). Pregnancy complicated by obsessive-compulsive disorder. Journal of Maternal-Fetal Medicine, 6, 31-34.
22. CHIU, C.C., HUANG, S.Y., SHEN, W. & SU, K.P. (2003). Omega-3 fatty acids for depression in pregnancy. American Journal of Psychiatry, 160, 385.
23. CHUNG, T.K., LAU, T.K., YIP, A.S., CHIU, H.F. & LEE, D.T. (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosomatic Medicine, 63(5), 830-834.
24. CLAES, M., MAES, M. & JACQUEMYN, Y. (1997). The contribution of biological factors to the pathogenesis of psychiatric disorders in the postpartum period: a survey. Acta Neuropsychiatrica, 9, 128-132.
25. COHEN, L.S., HELLER, V.L., BAILEY, J.W., GRUSH, L., ABLON, J.S. & BOUFFARD, S.M. (2000). Birth outcomes following prenatal exposure to fluoxetine. Biological Psychiatry, 48, 996-1000.
26. COHEN, L.S., FRIEDMAN, J.M., JEFFERSON, J.W., JOHNSON, E.M. & WEINER, M.L. (1994). A re-evaluation of the risk of in utero exposure to lithium. Journal of the American Medical Association, 271, 146-150.
27. COHEN, L.S. & ROSENBAUM, J.F. (1998). Psychotropic drug use during pregnancy: weighing the risks. Journal of Clinical Psychiatry, 59(Suppl. 2), 18-28.
28. COHEN, L.S., ROSENBAUM, J.F. & HELLER, V.L. (1989). Panic attack-associated placental abruption: a case report. Journal of Clinical Psychiatry, 50, 266-267.
29. COHEN, L.S., SICHEL, D.A., FARAONE, S.V., ROBERTSON, L.M., DIMMOCK, J.A. & ROSENBAUM, J.F. (1996). Course of panic disorder during pregnancy and the puerperium: a preliminary study. Biological Psychiatry, 39, 950-954.
30. COHEN, L.S., SICHEL, D.A., ROBERTSON, L.M., HECKSCHER, E. & ROSENBAUM, J.F. (1995). Post-partum prophylaxis for women with bipolar disorder. American Journal of Psychiatry, 152, 1641-1645.
31. COSTEI, A.M., KOZER, E., HO, T., ITO, S. & KOREN, G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatric & Adolescent Medicine, 156, 1129-1132.
32. COTT, J. (2000). Omega-3 fatty acids and pregnancy. Alternative Therapies in Women's Health, 2(12), 89-92.
33. COVERDALE, J.H., MCCULLOUGH, L.B. & CHERVENAK, F.A. (2002). Enhancing decision-making by depressed pregnant patients. Journal of Perinatal Medicine, 30(4), 349-351.
34. COWE, L., LLOYD, D.J. & DAWLING, S. (1982). Neonatal convulsions caused by withdrawal from maternal clomipramine. British Medical Journal, 284, 1837-1838.
35. DAYAN, J., CREVEUIL, C., HERLICOVIEZ, M., HERBEL, C., BARANGER, E., SAVOYE, C. & THOUIN, A. (2002). Role of anxiety and depression in the onset of spontaneous preterm labor. American Journal of Epidemiology, 155(4), 293-301.
36. DEBER, R.B., KRAETSCHMER, N. & IRVINE, J. (1996). What role do patients wish to play in decision-making? Archives in Internal Medicine, 156, 1414-1420.
37. DELGADO-ESCUETA, A.V. & JANZ, D. (1992). Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology, 42(Suppl. 5), 149-160.
38. DESMOND, M.M., RUDOLPH, A.J. & HILL, R.M. (1967). Behavioral alterations in infants born to mothers on psychoactive medication during pregnancy. In: G. FARRELL (Ed), Congenital Mental Retardation. Austin: University of Texas.
39. DICKSON, R.A. & HOGG, L. (1998). Pregnancy of a patient treated with clozapine. Psychiatric Services, 49, 1081-1083.
40. DOLOVICH, L.R., ADDIS, A., VAILLANCOURT, J.M., POWER, J.D., KOREN, G. & EINARSON, T.R. (1998). Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. British Medical Journal, 317, 839-843.
41. EINARSON, A., FATOYE, B., SARKAR, M., LAVIGNE, S.V., BROCHU, J., CHAMBERS, C., MASTROIACOV, P., ADDIS, A., MATSUI D., SCHULER, L., EINARSON, T.R. & KOREN, G. (2001). Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. American Journal of Psychiatry, 158, 1728-1730.
42. ERICSON, A., KALLEN, B. & WIHOLM, B. (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology, 55, 503-508.
43. ERNST, C.L. & GOLDBERG, J.F. (2002). The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. Journal of Clinical Psychiatry, 63(Suppl. 4), 42-55.
44. EVANS, J., HERON, J., FRANCOMB, H., OKE, S. & GOLDING, J. (2001). Cohort study of depressed mood during pregnancy and after childbirth. British Medical Journal, 323, 257-260.
45. FDA (1999). Concept paper on pregnancy labeling. Summary of comments from a public hearing and model pregnancy labeling based on recommendations. May 20, 1999. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3516r1.doc.
46. FERRILL, M.J., KEHOE, W.A. & JACISIN, J.J. (1992). ECT during pregnancy: physiologic and pharmacologic considerations. Convulsant Therapy, 8, 186-200.
47. FRANK, E., KUPFER, D.J., PEREL, J.M., CORNES, C., JARRETT, D.B., MALLINGER, A.G., THASE, M.E., MCEACHRAN, A.B. & GROCHOCHINSI, V.J. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives in General Psychiatry, 47, 1093-1099.
48. FREEMAN, M.P. (2000). Omega-3 fatty acids in psychiatry: a review. Annals in Clinical Psychiatry, 12, 159-165.
49. FREEMAN, M.P., WOSNITZER-SMITH, K., FREEMAN, S.A., MCELROY, S.L., KMETZ, G.F., WRIGHT, R. & KECK, P.E. JR. (2002). The impact of reproductive events on the course of bipolar disorder in women. Journal of Clinical Psychiatry, 63, 284-287.
50. GEORGE, D.T., LADENHEIM, J.A. & NUTT, D.J. (1987). Effects of pregnancy on panic attacks. American Journal of Psychiatry, 144, 1078-1079.
51. GOLDSTEIN, D.J., CORBIN, L.A. & FUNG, M.C. (2000). Olanzapine-exposed pregnancies and lactation: early experience. Journal of Clinical Psychopharmacology, 20, 399-403.
52. GOTLIB, I.H., WHIFFEN, V.E., MOUNT, J.H., MILNE, K. & CORDY, N.I. (1989). Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. Journal of Consulting Clinical Psychology, 57, 269-274.
53. GRACIOUS, B.L. & WISNER, K.L. (1997). Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depression & Anxiety, 6, 124-128.
54. GRANSTROM, M.L. (1982). Development of the children of epileptic mothers - preliminary results from the prospective Helsinki study. In: D. JANZ, L. BOSSI & M. DAM et al., (Eds), Epilepsy, Pregnancy, and the Child (pp. 403-408). New York: Raven Press.
55. GROF, P., ROBBINS, W., ALDA, M., BERGHOEFER, A, VOJTECHOVSKY, M., NILSSON, A. & ROBERTSON, C. (2000). Protective effect of pregnancy in women with lithium-responsive bipolar disorder. Journal of Affective Disorders, 61(1-2), 31-39.
56. GUAY, J., GRENIER, Y. & VARIN, F. (1998). Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. Clinical Pharmacokinetics, 34, 483-496.
57. HARTZ, S.C., HEINONEN, O.P., SHAPIRO, S., SISKIND, V. & SLONE, D. (1975). Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. New England Journal of Medicine, 292, 726-728.
58. HEIKKINEN, T., EKBLAD, U., KERO, P., EKBLAD, S. & LAINE, K. (2002). Citalopram in pregnancy and lactation. Clinical Pharmacology & Therapy, 72, 184-191.
59. HEINONEN, O.P., SLONE, D. & SHAPIRO, S. (1977). Birth defects and drugs in pregnancy. Littleton, Mass: Publishing Science Group.
60. HENDRICK, V. & ALTSHULER, L. (2002). Management of major depression during pregnancy. American Journal of Psychiatry, 159(10), 1667-1673.
61. HENDRICK, V.C. & ALTSHULER, L.L. (1997). Management of breakthrough panic disorder symptoms during pregnancy (letter). Journal of Clinical Psychopharmacology, 17, 228-229.
62. HIBBELN, J.R. (2002). Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-sectional, ecological analysis. Journal of Affective Disorders, 69, 15-29.
63. HOLMES, L.B., HARVEY, E.A., COULL, B.A., HUNTINGDON, K.B., KHOSHBIN, S., HAYES, A.M. & RYAN, L.M. (2001). The teratogenicity of anticonvulsant drugs. New England Journal of Medicine, 334, 1132-1138.
64. HOSTETTER, A., STOWE, Z.N., STRADER, J.R. JR., MCLAUGHLIN, E. & LLEWELLYN, A. (2000). Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depression & Anxiety, 11(2), 51-57.
65. HUTCHINGS, D.E. (1983). Behavioral teratology: a new frontier in neurobehavioral research. In: E.M. JOHNSON & D.M. KOCHHAR (Eds), Teratogenesis and Reproductive Toxicology (pp. 207-235). New York: Springer Verlag.
66. ISTVAN, J. (1986). Stress, anxiety, and birth outcomes: a critical review of the evidence. Psychological Bulletin, 100, 331-348.
67. IQBAL, M.M., GUNDLAPALLI, S.P., RYAN, W.G., RYALS, T. & PASSMAN, T.E. (2001). Effects of anti-manic mood-stabilizing drugs on fetuses, neonates, and nursing infants. Southern Medicine Journal, 94, 304-322.
68. JACOBSON, S.J., JONES, K., JOHNSON, K., CEOZIN, L., KAUR, P., SAHN, D., DONNENFELD, A.E., RIEDER, M., SANTELLI, R. & SMYTHE, J. (1992). Prospective multicenter study of pregnancy outcome after lithium exposure during first trimester. Lancet, 339, 530-533.
69. JOHANSON, R., CHAPMAN, G., MURRAY, D., JOHNSON, I. & COX, J. (2000). The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. Journal of Psychosomatic Obstetrics & Gynecology, 21(2), 93-97.
70. KENDELL, R.E., CHALMERS, J.C. & PLATZ, C. (1987). Epidemiology of puerperal psychoses. British Journal of Psychiatry, 150, 662-673.
71. KENT, L.S. & LAIDLAW, J.D. (1995). Suspected congenital sertraline dependence. British Journal of Psychiatry, 167, 412-413.
72. KESSLER, R.C., MCGONAGLE, K.A., ZHAO, S., NELSON, C.B., HUGHES, M., ESHLEMAN, S., WITTCHEN, H.U. & KENDLER, K.S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives in General Psychiatry, 51, 8-19.
73. KOREN, G., BOLOGA, M., LONG, D., FELDMAN, Y. & SHEAR, N.H. (1989). Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. American Journal of Obstetrics & Gynecology, 160, 1190-1194.
74. KOREN, G., COHN, T., CHITAYAT, D., KAPUR, B., REMINGTON, G., REID, D.M. & ZIPURSKY, R.B. (2002). Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. American Journal of Psychiatry, 159, 136-137.
75. KULIN, N.A., PASTUSZAK, A., SAGE, S.R., SCHICK-BOSCHETTO, B., SPIVEY, G., FELDKAMP, M., ORMOND, K., MATSUI, D., STEIN-SCHECHMAN, A.K., COOK, L., BROCHU, J., RIEDER, M. & KOREN, G. (1998). Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Journal of the American Medical Association, 279, 609-610.
76. KURKI, T., HIILESMAA, V., RAITASALO, R., MATTILA, H. & YLIKORKALA, O. (2000). Depression and anxiety in early pregnancy and risk for preeclampsia. Obstetrics & Gynecology, 95, 487-490.
77. LAEGREID, L., OLEGARD, R., CONRADI, N., HAGBERG, G., WAHLSTROM, J. & ABRAHAMSSON, L. (1990). Congenital malformations and maternal consumption of benzodiazepines: a case control study. Developmental Medicine & Child Neurology, 32, 432-441.
78. LAMOTRIGINE PREGNANCY REGISTRY. (2002). Interim report, September 1992 through March 2001. GlaxoSmith Kline Corporation, Research Triangle, NC.
79. LIER, L., KASTRUP, M. & RAFAELSEN, O.J. (1989). Psychiatric illness in relation to childbirth and pregnancy, II: diagnostic profiles, psychosocial and perinatal aspects. Nordisk Psykiatrisk Tidsskrift, 43, 535-542.
80. LINDHOUT, D. & OMTZIGT, J.G.C. (1994). Teratogenic effects of anti-epileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia, 35, 519-528.
81. LWEZEY, G.T. & RAYBURN, W.F. (1992). Principles of perinatal pharmacology. In: W.F. RAYBURN & F.P. ZUSPAN (Eds), Drug Therapy in Obstetrics and Gynecology, 3rd edition. (pp. 3-12). St. Louis: Mosby Year Book Inc.
82. LLEWELLYN, A., STOWE, Z.N. & STRADER J.R. JR. (1998). The use of lithium and management of women with bipolar disorder during pregnancy and lactation. Journal of Clinical Psychiatry, 59(Suppl. 6), 57-64.
83. MAES, M., VERKERK, R., BONACCORSO, S., OMBELET, W., BOSMANS, E. & SCHARPE, S. (2002). Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon that is related to immune activation. Life Sciences, 71, 1837-1848.
84. MANBER, R., ALLEN, J.J.B. & MORRIS, M.M. (2002). Alternative treatments for depression: empirical support and relevance to women. Journal of Clinical Psychiatry, 63, 628-640.
85. MCELHATTON, P.R. (1994). The effects of benzodiazepine use during pregnancy and lactation. Reproductive Toxicology, 8, 461-475.
86. MCNEIL, T.F. & MALMQUIST-LARSSON, A. (1984). Women with non-organic psychosis: mental disturbance during pregnancy. Acta Psychiatrica Scandinavica, 70, 127-139.
87. MHANNA, M.J., BENNET, J.B. & IZATT, S.D. (1997). Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics, 100, 158-159.
88. MILLER, L.J. (1994). Use of electroconvulsive therapy during pregnancy. Hospital & Community Psychiatry, 45, 444-450.
89. MOORE, K.L. & PERSAUD, T.V. (1998). The developing human: clinically oriented embryology, 6th edition. Philadelphia: WB Saunders Co.
90. NAHAS, Z., BOHNING, D.E., MOLLOY, M.A., OUSTZ, J.A., RISCH, S.C. & GEORGE, M.S. (1999). Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. Journal of Clinical Psychiatry, 60, 50-52.
91. NEMETS, B., STAHL, Z. & BELMAKER, R.H. (2002). Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry, 159, 477-479.
92. NEWPORT, D.J., WILCOX, M.M. & STOWE, Z.N. (2001). Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Seminars in Perinatology, 25, 177-190.
93. NEZIROGLU, F., ANEMONE, R. & YARYURA-TOBIAS, J.A. (1992). Onset of obsessive-compulsive disorder in pregnancy. American Journal of Psychiatry, 149, 947-950.
94. NILSSON, E., LICHTENSTEIN, P., CNATTINGIUS, S., MURRAY, R.M. & HULTMAN, C.M. (2002). Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophrenia Research, 58, 221-229.
95. NORTHCOTT, C.J. & STEIN, M.B. (1994). Panic disorder in pregnancy. Journal of Clinical Psychiatry, 55, 539-542.
96. NULMAN, I., ROVET, J., STEWART, D.E., WOLPIN, J., GARDNER, H.A., THEIS, J.G., KUHN, N. & KOREN, G., for the Motherisk Program, Hospital for Sick Children and University of Toronto (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine, 336, 258-262.
97. NULMAN, I., ROVET, J., STEWART, D.E., WOLPIN, J., PACE-ASCIAK, P., SHUHAIBER, S. & KOREN, G., for the Motherisk Program, Hospital for Sick Children and University of Toronto (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. American Journal of Psychiatry, 159(11), 1889-1895.
98. O'CONNOR, T.G., HERON, J., GOLDING, J., BEVERIDGE, M. & GLOVER, V. (2002). Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. British Journal of Psychiatry, 180, 502-508.
99. O'HARA, M.W., NEUNABER, D.J. & ZEKOSKI, E.M. (1984). Prospective study of postpartum depression: prevalence, course, and predictive factors. Journal of Abnormal Psychology, 93, 158-171.
100. OREN, D.A., WISNER, K.L., SPINELLI, M. EPPERSON, C.N., PEINOL, K.S., TERMAN, J.S. & TERMAN, M. (2002). An open trial of morning light therapy for treatment of anteparturn depression. American Journal of Psychiatry, 159, 666-669.
101. ORR, S.T. & MILLER, C.A. (1995). Maternal depressive symptoms and the risk of poor pregnancy outcome. Epidemiology Review, 17, 165-171.
102. PAJULO, M., SAVONLAHTI, E., SOURANDER, A., HELENIUS, H. & PIHA, J. (2001). Antenatal depression, substance dependency and social support. Journal of Affective Disorders, 65, 9-17.
103. PARRY, B.L., CURRAN, M.L., STUENKEL, C.A., YOKIMOZO, M., TAM, L., POWELL, K.A. & GILLIN, J.C. (2000). Can critically timed sleep deprivation be useful in pregnancy and postpartum depressions? Journal of Affective Disorders, 60, 201-212.
104. PASTUSZAK, A., SCHICK-BOSCHETTO, B. & ZUBER, C. (1993). Pregnancy outcome following first trimester exposure to fluoxetine (Prozac). Journal of the American Medical Association, 269, 2246-2248.
105. PATTON, S.W., MISRI, S., CORRAL, M.R., PERRY, K.F. & KUAN, A.J. (2002). Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Canadian Journal of Psychiatry, 47, 959-965.
106. PINELLI, J.M, SYMINGTON, A.J., CUNNINGHAM, K.A. & PAES, B.A. (2002). Case report and review of the perinatal implications of maternal lithium use. American Journal of Obstetrics & Gynecology, 187, 245-249.
107. PLATT, J.E., FRIEDHOFF, A.J., BROMAN, S.H., BOND, R.N., LASKA, E. & LIN, S.P. (1988). Effects of prenatal exposure to neuroleptic drugs on children's growth. Neuropsychopharmacology, 1, 205-212.
108. PURI, B.K., STEINER, R. & RICHARDSON, A.J. (1998). Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives in General Psychiatry, 55, 188-189.
109. RAYBURN, W.F., CHRISTENSEN, H.D., & GONZALEZ, C.L. (2000). Effect of antenatal exposure to Saint John's wort (Hypericum) on neurobehavior of developing mice. American Journal of Obstetrics & Gynecology, 183, 1225-1231.
110. RAYBURN, W.F., GONZALEZ, C.L., CHRISTENSEN, H.D. & STEWART, J.D. (2001). Effect of prenatally administered hypericum (St John's Wort) on growth and physical maturation of mouse offspring. American Journal of Obstetrics & Gynecology, 184, 191-195.
111. REGISTRY OF CLOZARIL® BABIES. (2002). Novartis Corp, East Hanover, NJ.
112. ROBINSON, L., WALKER, J.R. & ANDERSON, D. (1992). Cognitive-behavioral treatment of panic disorder during pregnancy and lactation. Canadian Journal of Psychiatry, 37, 623-626.
113. ROSA, F. (1994). Medicaid antidepressant pregnancy exposure outcome. Reproductive Toxicology, 8, 444-445.
114. SACKER, A., DONE, D.J. & CROW, T.J. (1996). Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. Psychological Medicine, 26, 279-287.
115. SAFRA, M.J. & OAKLEY, G.P. JR. (1975). Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet, 2, 478-480.
116. SAKS, B.R. (2001). Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: a report of 7 cases. Archives of Women's Mental Health, 4, 165-170.
117. SANDMAN, C.A., WADHWA, P.D., DUNKEL-SCHETTER, C., CHICZ-DEMET, A., BELMAN, J., PORTO, M., MURATA, Y., GARITE, T.J. & CRINELLA, F.M. (1994). Psychobiological influences of stress and HPA regulation on the human fetus and infant birth outcomes. Annals of the NY Academy of Science, 739, 198-210.
118. SCHOU, M. (1976). What happened to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatrica Scandinavica, 54, 193-197.
119. SCOLNIK, D., NULMAN, I. & RUVET, J. (1994). Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. Journal of the American Medical Association, 271, 767-770.
120. SHEAR, M.K. & MAMMEN, O. (1995). Anxiety disorders in pregnant and postpartum women. Psychopharmacological Bulletin, 31, 693-703.
121. SHNIDER, S.M. & LEVINSON, G. (1993). Anesthesia for Obstetrics, 3rd edition. Baltimore: William & Wilkins.
122. SIMINOFF, L.A. & FETTING, J.H. (1989). Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Medical Decision Making, 9, 262-271.
123. SIMON, G.E., CUNNINGHAM, M.L. & DAVIS, R.L (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry, 159(12), 2055-2061.
124. SLOVIC, P. (1987). Perception of risk. Science, 36, 280-285.
125. SPINELLI, M.G. (1997). Interpersonal psychotherapy for depressed antepartum women: a pilot study. American Journal of Psychiatry, 154, 1028-1030.
126. ST CLAIR, S.M. & SCHIRMER, R.G. (1992). First-trimester exposure to alprazolam. Obstetrics & Gynecology, 80, 843-846.
127. STEER, R.A., SCHOLL, T.O., HEDIGER, M.L. & FISCHER, R.L. (1992). Self-reported depression and negative pregnancy outcomes. Journal of Clinical Epidemiology, 45, 1093-1099.
128. STOLL, A.L., SEVERUS, E., FREEMAN, M.P., RUETER, S., ZBOYAN, H.A., DIAMOND, E., CRESS, K.K. & MARANGELL, L.B. (1999). Omega-3 fatty acids in bipolar disorder: a double-blind placebo-controlled trial. Archives in General Psychiatry, 56, 407-412.
129. STONER, S.C., SOMMI, R.W. JR. & MARKEN, P.A. (1997). Clozapine use in two full-term pregnancies (letter). Journal of Clinical Psychiatry, 58, 364-365.
130. STOTT, D.H. (1973). Follow-up study from birth of the effects of prenatal stresses. Developmental Medicine & Child Neurology, 15, 770-787.
131. SU, K., SHEN, W.W. & HUANG, S. (2001). Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. European Neuropsychopharmacology, 11, 295-299.
132. TERMAN, M., TERMAN, J.S. & ROSS, D.C. (1998). A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Archives in General Psychiatry, 55, 875-882.
133. VIGGEDAL, G., HAGBERG, B.S., LAEGREID, L. & ARONSSON, M. (1993). Mental development in late infancy after prenatal exposure to benzodiazepines - a prospective study. Journal of Child Psychology & Psychiatry, 34, 295-305.
134. VIGUERA, A.C., COHEN, L.S., BALDESSARINI, R.J. & NONACS, R. (2002a). Managing bipolar disorder during pregnancy: weighing the risks and benefits. Canadian Journal of Psychiatry, 47, 426-436.
135. VIGUERA, A.C., COHEN, L.S., BOUFFARD, S., WHITFIELD, T.H. & BALDESSARINI, R.J. (2002b). Reproductive decisions by women with bipolar disorder after pre-pregnancy psychiatric consultation. American Journal of Psychiatry, 159(12), 2102-2104.
136. VIGUERA, A.C., NONACS, R., COHEN, L.S., TONDO, L., MURRAY, A. & BALDESSARINI, R.J. (2000). Risk of recurrence of bipolar disorder in pregnant and non-pregnant women after discontinuing lithium maintenance. American Journal of Psychiatry, 157, 179-184.
137. VIGUERA, A.C., MCCARTHY, C., WHITFIELD, T.H., POITRA, J.R., BEKKEN, K. & SHERMAN, J. (2001). Neurobehavioral outcome following lithium exposure: what happens to lithium babies. New Orleans: American Psychiatric Association.
138. VILLEPONTEAUX, V.A., LYDIARD, R.B., LARAIA, M.T., STUART, G.W. & BALLENGER, J.C. (1992). The effects of pregnancy on pre-existing panic disorder. Journal of Clinical Psychiatry, 53, 201-203.
139. VITIELLO, B. (1998). Pediatric psychopharmacology and the interaction between drugs and the developing brain. Canadian Journal of Psychiatry, 43, 582-584.
140. WADHWA, P.D., SANDMAN, C.A., PORTO, M., DUNKEL-SCHETTER, C. & GARITE, T.J. (1993). The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. American Journal of Obstetrics & Gynecology, 169, 858-865.
141. WALDMAN, M.D. & SAFFERMAN, A.Z. (1993). Pregnancy and clozapine. American Journal of Psychiatry, 150, 168-169.
142. WARE, M.R. & DEVANE, C.L. (1990). Imipramine treatment of panic disorder during pregnancy (letter). Journal of Clinical Psychiatry, 51, 482-484.
143. WEBSTER, P.A. (1973). Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet, 2, 318-319.
144. WEINSTEIN, M.R. & GOLDFIELD, M. (1975). Cardiovascular malformations with lithium use during pregnancy. American Journal of Psychiatry, 132, 529-531.
145. WEISBERG, R.B. & PAQUETTE, J.A. (2002). Screening and treatment of anxiety disorders in pregnant women. Women's Health Issues, 12, 32-36.
146. WILLIAMS, K.E. & KORAN, L.M. (1997). Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. Journal of Clinical Psychiatry, 58(7), 330-334.
147. WILSON, J.G. (1977). Current status of teratology: general principles and mechanisms derived from animal studies. In: J.G. WILSON & F.C. FRASER (Eds), Handbook of Teratology, General Principles and Etiology (pp. 47-74). New York: Plenum Press.
148. WISNER, K.L., GELENBERG, A.J., LEONARD, H., ZARIN, D. & FRANK, E. (1999). Pharmacologic treatment of depression during pregnancy. Journal of the American Medical Association, 282, 1264-1269.
149. WISNER, K.L., PEINDL, K.S. & HANUSA, B.H. (1996). Effects of childbearing on the natural history of panic disorder with comorbid mood disorder. Journal of Affective Disorders, 41(3), 173-180.
150. WISNER, K.L., PEINDL, K.S. & PEREL, J.M. (2002). Verapamil treatment for women with bipolar disorder. Biological Psychiatry, 51, 745-752.
151. WISNER, K.L. & PEREL, J.M. (1988). Psychopharmacologic agents and electroconvulsive therapy during pregnancy and the puerperium. In: R.L. COHEN (Ed), Psychiatric Consultation in Childbirth Settings (pp. 165-206). New York: Plenum.
152. WISNER, K.L., PEREL, J.M. & WHEELER, S.B. (1993). Tricyclic dose requirements across pregnancy. American Journal of Psychiatry, 150, 1541-1542.
153. WISNER, K.L., ZARIN, D.A., HOLMBOE, E.S., APPELBAUM, P.S., GELENBERG, A.J., LEONARD, H.L. & FRANK, E. (2000). Risk-benefit decision making for treatment of depression during pregnancy. American Journal of Psychiatry, 157(12), 1933-1940.
154. WU, J., VIGUERA, A., RILEY, L., COHEN, L. & ECKER, J. (2002). Mood disturbance in pregnancy and the mode of delivery. American Journal of Obstetrics & Gynecology, 187(4), 864-867.
155. YERBY, M.S. (1987). Problems and management of the pregnant woman with epilepsy. Epilepsia, 28(Suppl. 3), 29-36.
156. YOUNG, S.A., CAMPBELL, N. & HARPER, A. (2002). Depression in women of reproductive age. Considerations in selecting safe, effective therapy. Postgraduate Medicine, 112(3), 45-50.
157. ZANARINI, M.C. & FRANKENBURG, F.R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169.
158. ZUCKERMAN, B., AMARO, H., BAUCHNER, H. & CABRAL, H. (1989). Depressive symptoms during pregnancy: relationship to poor health behaviors. American Journal of Obstetrics & Gynecology, 160, 1107-1111.